DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5bgxps/hematological) has announced the addition of the "Hematological Cancers Drug Pipeline Update 2014" report to their offering.
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.
There are today 438 companies plus partners developing 737 hematological cancer drugs in 1563 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 228 drugs. Hematological Cancers Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 386 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date, 369 out of the 374 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 74 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed # 93
- Registered # 1
- Pre-registration # 4
- Phase III # 65
- Phase II # 270
- Phase I # 283
- Preclinical # 206
- No Data # 14
- Suspended # 8
- Ceased # 228
For more information visit http://www.researchandmarkets.com/research/5bgxps/hematological